Literature DB >> 11425505

A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects.

N P Verhoeff1, S Kapur, D Hussey, M Lee, B Christensen, G Papatheodorou, R B Zipursky.   

Abstract

The effect of endogenous dopamine (DA) on measurement of neostriatal DA D(2) receptor binding potential (D(2)RBP) in vivo was evaluated with positron emission tomography (PET) and the radiotracer [11C]raclopride by comparing the D(2)RBP before and after acute DA depletion. DA depletion was achieved by per-oral administration of 4.5 g alpha-methyl-para-tyrosine (AMPT) given in 25 h. Six healthy subjects completed the protocol. The AMPT treatment increased D(2)RBP significantly from 3.11 +/- 0.25 to 3.68 +/- 0.23 and decreased plasma levels of the DA metabolite homovanillic acid by 71 +/- 11% and levels of the norepinephrine metabolite 3-methoxy-4-hydroxyphenethyleneglycol by 53 +/- 7%. Increase in D(2)RBP correlated with decrease in attentiveness and with increase in errors of commission from Conners' Continuous Performance Test. On AMPT, a significant decrease in subjective happiness scores was observed. The results imply that a noninvasive [11C]raclopride PET protocol coupled with relatively brief administration of a rather low total dose of AMPT resulted in measurable acute DA depletion that might provide estimates of synaptic neostriatal DA concentration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425505     DOI: 10.1016/S0893-133X(01)00231-7

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  19 in total

1.  Examining endogenous dopamine in treated schizophrenia using [¹¹C]-(+)-PHNO positron emission tomography: A pilot study.

Authors:  Fernando Caravaggio; Carol Borlido; Alan Wilson; Ariel Graff-Guerrero
Journal:  Clin Chim Acta       Date:  2015-03-23       Impact factor: 3.786

2.  Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.

Authors:  Tanja Veselinović; Holger Schorn; Ingo Vernaleken; Katharina Schiffl; Christoph Hiemke; Gerald Zernig; Ruben Gur; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2011-06-04       Impact factor: 4.530

3.  Neural correlates of sleepiness induced by catecholamine depletion.

Authors:  Noah Meyers; Stephen Fromm; David A Luckenbaugh; Wayne C Drevets; Gregor Hasler
Journal:  Psychiatry Res       Date:  2011-08-27       Impact factor: 3.222

4.  Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia.

Authors:  Fernando Caravaggio; Margaret Hahn; Shinichiro Nakajima; Philip Gerretsen; Gary Remington; Ariel Graff-Guerrero
Journal:  Med Hypotheses       Date:  2015-06-24       Impact factor: 1.538

5.  Model-based parametric study of frontostriatal abnormalities in schizophrenia patients.

Authors:  Shoji Tanaka
Journal:  BMC Psychiatry       Date:  2010-02-27       Impact factor: 3.630

6.  Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain.

Authors:  Fernando Caravaggio; Lawrence S Kegeles; Alan A Wilson; Gary Remington; Carol Borlido; David C Mamo; Ariel Graff-Guerrero
Journal:  Synapse       Date:  2016-07-11       Impact factor: 2.562

7.  Increased synaptic dopamine in the putamen in restless legs syndrome.

Authors:  Christopher J Earley; Hiroto Kuwabara; Dean F Wong; Charlene Gamaldo; Rachel E Salas; James R Brašić; Hayden T Ravert; Robert F Dannals; Richard P Allen
Journal:  Sleep       Date:  2013-01-01       Impact factor: 5.849

Review 8.  The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review.

Authors:  Fernando Caravaggio; Shinichiro Nakajima; Eric Plitman; Philip Gerretsen; Jun Ku Chung; Yusuke Iwata; Ariel Graff-Guerrero
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-09-01       Impact factor: 5.067

9.  Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO.

Authors:  Fernando Caravaggio; Shinichiro Nakajima; Carol Borlido; Gary Remington; Philip Gerretsen; Alan Wilson; Sylvain Houle; Mahesh Menon; David Mamo; Ariel Graff-Guerrero
Journal:  Neuropsychopharmacology       Date:  2014-05-30       Impact factor: 7.853

10.  A receptor-based model for dopamine-induced fMRI signal.

Authors:  Joseph B Mandeville; Christin Y M Sander; Bruce G Jenkins; Jacob M Hooker; Ciprian Catana; Wim Vanduffel; Nathaniel M Alpert; Bruce R Rosen; Marc D Normandin
Journal:  Neuroimage       Date:  2013-03-01       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.